GlassScriptPhysician profile
Lashelle F Barmore
NPI 1902177611
$485,610.33
in general payments reported to CMS, 2019-2025
40 companies · $79K in 2025
The $79K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $70K · 2021: $88K · 2022: $68K · 2023: $41K · 2024: $39K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Travel and Lodging: $20K · Honoraria: $16K · Food and Beverage: $4,252 · Consulting Fee: $3,005 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,867.13 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,812.00 |
| Travel and Lodging | $20,238.81 |
| Honoraria | $15,615.00 |
| Food and Beverage | $4,252.24 |
| Consulting Fee | $3,005.00 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $241,839.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $137,386.39 | 2019-2025 | Korlym |
| Dexcom, INC. | $30,381.28 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Lilly USA, LLC | $29,006.58 | 2019-2022 | |
| Medtronic, INC. | $18,367.30 | 2021-2023 | Minimed 780g |
| Medtronic Minimed, INC. | $10,693.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $10,447.35 | 2019-2023 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $2,527.74 | 2019-2021 | |
| Abbott Laboratories | $827.59 | 2020-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $535.29 | 2019-2022 | |
| Abbvie INC. | $452.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $330.81 | 2021-2022 | |
| Pfizer INC. | $329.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $317.30 | 2019-2021 | |
| Allergan, INC. | $287.60 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lashelle Barmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.